P46375 8th Annual Cell Line Development and Engineering Asia
Download Brochure Request

Register your interest

Comments

Register your interest

Comments

8th Annual Cell Line Development and Engineering Asia

14 – 16 May 2019, Shanghai Marriott Hotel Parkview, China.

Book Now Register Your Interest

LOCAL CHINA COMPANIES RATES AVAILABLE. 中国企业可享有独家优惠价!
SPECIAL GROUP RATES FOR 2 OR MORE. 2名及以上代表注册立享团队优惠价。SEE PRICING BELOW.

overview

The global market size for cell line development is expected to exceed USD 7.5 billion by 2024. Some key market drivers include the demand for cell therapies, growing oncology market, increasing demand for vaccines and monoclonal antibodies, and continued growth in the vaccine market.

Aimed at providing a commercial snapshot of new market opportunities, yet retaining its focus on scientific and technical best practice use cases, the 8th Annual Cell Line Development & Engineering Asia summit will continue to provide unique learning and sharing opportunities for the industry.

Discussion themes

  • Impact of the surging biologics and cell therapy market on cell line development
  • Cell line market trends by source – mammalian and non-mammalian, and influencing factors
  • Market outlook for cell lines across drug discovery, bioproduction, toxicity testing, and tissue engineering
  • CAR-T cell development and manufacturing
  • Growth prospects in the primary cell line and tissue engineering
  • Use cases of 3D cell culture in primary cell lines
  • The growing use of reagents and media, and technical best practice
  • In-source or out-source cell line development
  • Best practice to ensure clonality in new cell lines and legacy cell lines
  • Procs and cons of generation sequencing (NGS) for proving the clonality of legacy production cell lines
  • The use of synthetic biology to help understand success and failure in cell line development
  • CRIPSR in cell line development
  • Comparingculture methods – batch, fedbatch, and perfusion processes
  • Tailoring cell line development programs for your project

Part of

5th Annual BioPharma Development and Production Week »

With demonstrated success year on year, IBC’s BioPharma Development and Production Week in China enjoys unparalleled industry support. Known for generating knowledge, creating business opportunities, and bringing innovative ideas to the table, the BDP Week is now more impactful than ever with 5 high-level conferences, learning seminars, focused trade shows and business matching to boot.

Co located conferences

agenda

8:00 am

Registration Starts & Morning Coffee

9:00 am

Chairperson’s Opening Remarks

OPENING KEYNOTE SESSIONS JOINT PLENARY SESSIONS WITH 9TH ANNUAL BIOMANUFACTURING, 10TH ANNUAL BIOSIMILARS ASIA, 4TH ANNUAL CLINICAL TRIALS, CELL & GENE THERAPY CONFERENCES

Biopharma Innovation Keynote Enabling the Future of On-Demand Production & Transformative Medicines

Dan Gibson, Ph.D., Vice President, DNA Technology, Synthetic Genomics Inc.

10:30 am

Morning Networking & Refreshment Break

ASSURANCE AND PROOF OF MONOCLONALITY

11:20 am

Case Study and Application of Plate Imaging Systems for Clonality

George Hutchinson, Head of Global Distribution, Solentim, UK

11:50 am

  • Pros and cons of using transposase-mediated integration over site-directed or random integration of plasmid DNA
  • Higher titers for stable transfection pools, and higher titers with improved stability for clones by using transposase
  • Assurance of monoclonality in one seeding and imaging step by use of the Verified In-Situ Plate Seeding (VIPS) system

12:25 pm

Tech Implementations and Modeling Approaches

Brian Hosung Min, Senior Vice President, Samsung Bioepis, South Korea

1:00 pm

Networking Lunch

ADVANCES IN GENOME EDITING TECHNOLOGIES – CRISPR & CAR-T

2:00 pm

CRISPR in Cell Line Development: Applications of CRISPR in Rapid Development of Stable Transgene CHO Cell Lines

Jianwei Zhu, Chair Professor and Dean of School of Pharmacy, Shanghai Jiao Tong University (SJTU); Director of MOE Engineering Research Center of Cell Engineering and Antibody; President and Chief Executive Officer, Jecho Biopharmaceuticals, China

2:30 pm

CAR-T Cell Development and Manufacturing: Cell Line Development in CAR-T: Advances in New Host Cells, Cell Culture Applications

Steve Oh, Institute Professor and Scientist at the Bioprocessing Technology Institute, A-STAR, Singapore

3:00 pm

  • Current IP landscape, key considerations to the future of gene editing, future applications and developments

3:30 pm

Afternoon Networking & Refreshment Break

CONTINUOUS MANUFACTURING AND PURIFICATION

4:00 pm

Developments in End-to-End Continuous Cell Culture and Manufacturing

Xiaoming (Jerry) Yang, Senior Vice President, Process & Product Development, Just Biotherapeutics, China

5:30 pm

Cell Culture and Purification Process Development Strategy from Analytical Approach

Eric Chang, Head of Cell Line Development, JHL Biotech, Taiwan

6:00 pm

Chairperson’s Summary and End of Conference Day 1

8:30 am

Morning Coffee

8:50 am

Chairperson’s Opening Remarks

ACCELERATING CELL LINE DEVELOPMENT AND CASE STUDIES

9:00 am

  • Overview of global regulatory standpoints on use of CRISPR and genome editing tools in cell engineering
  • Use of pool cell lines for pre-clinical materials in accelerating cell line development
  • Rise of platform technologies and implications on data integration and management
  • Regulatory pathways and requirements in clonality, characterization, qualification

10:00 am

  • How we can evaluate biochemical and biological activities?
  • How we can manufacture the bispecific antibody in large scale for its clinical trial?
  • Summarized results of current clinical study of ABL001 (NOV1501)

10:30 am

Morning Networking & Refreshment Break

NEW TECHNOLOGIES AND HOST CELL LINES

11:30 am

Spotlight Presentation in Characterisation, Small-Scale Analysis, Stable Cell Lines, Quality, Titre

James (Jianguo) Yang, Chief Executive Officer, Tayu Huaxia Biotech Medical Group, China

12:00 pm

Spotlight Presentation in New Host Cell Lines

Doug Chen, Vice President, CMC, I-Mab Biopharma, China

12:30 pm

Networking Lunch

HIGH THROUGHPUT PLATFORMS FOR CELL LINE DEVELOPMENT

1:30 pm

  • Presented emerging trends and technologies for CHO cell line development and engineering
  • Discussed mammalian systems biotechnology for targeted and precise CHO cell line development and engineering
  • Integrated multi-omics profiles with a genome-scale metabolic model of CHO cells

2:30 pm

Development of Analytical Platforms to Support Process Optimization and PAT

Dr. John E. Gil IV, Director, Head of Cell Line Generation, Shire HGT, U.S

3:00 pm

Panel Discussion: Rise of Platform Technologies: Automation and Big Data Integration in CLD

Dr. John E. Gil IV, Director, Head of Cell Line Generation, Shire HGT, U.S

Dong-Yup Lee, Associate Professor, College of Engineering, Sung Kyun Kwan University (SKKU), South Korea

Dr. Senyon Choe (Teddy), Professor Biology, University of California San Diego (UCSD), USA, President/Director of joint Center for Biosciences, Korea

3:30 pm

Afternoon Networking & Refreshment Break

CLOSING PLENARY PANEL JOINT PLENARY SESSIONS WITH 9TH ANNUAL BIOMANUFACTURING, 10TH ANNUAL BIOSIMILARS ASIA, 4TH ANNUAL CLINICAL TRIALS, CELL & GENE THERAPY CONFERENCES

5:00 pm

Chairperson’s Summary and End of Conference

pricing

Packages Price
2 Day Conference - International Companies, Global HQ Located Outside ChinaUS $1895US $1695Early BirdEarly Bird
2 Day Conference - Local China CompaniesUS $977US $827Early BirdEarly Bird
Group Rate of 2 or more delegates - International Companies, Global HQ Located Outside ChinaUS $1495Early Bird
Group of 2 or more delegates - Local China CompaniesUS $752Early Bird
Group Rate of 4 or more delegates - International Companies, Global HQ Located Outside ChinaUS $1295Early Bird
Group of 4 or more delegates - Local China CompaniesUS $676Early Bird

Early Bird Rate: Register & Pay by 16 March 2019

  • Multiple Bookings Discount pricing is applicable to groups of 2 or more delegates from the same organisation registering for the same event, at the same time.
  • Fee stated is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR group rate.
  • All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.
  • All delegates from Singapore-based companies are required to pay an additional 7% GST (SINGAPORE EVENTS ONLY)

Register Your Interest

Receive updates on this event. Leave your details with us and we will notify you of updates as they happen.

Register your interest here >>

Sponsorship

Partnership and Profile Building Opportunities are Now Available!
Contact us today to find out how you can position your company as a market leader at this event, and to explore the range of branding and marketing opportunities available.

View Sponsors and Exhibitors profile >>

speakers

Dan Gibson, Ph.D.

Vice President, DNA Technology, Synthetic Genomics Inc.

Richard Wang

CEO, Fosun Kite Biotech, China

He Ting

Chief Executive Officer, ImmunoChina, China

Dong Wei

CEO, Edigene, China

Zonghai Li

President and Chief Executive Officer, CARsgen Therapeutics, China

Peter Luo

CEO, Adagene Pharma, China

Ruirong Yuan

President, Chief Medical Officer and Board Director, Adlai Nortye Biopharma, China

Eddy Wu

China Head/Vice-President, Terns Pharmaceutical, China

Jonathan Zhao 4th Annual Bioprocess and Technology 2018

Jonathan Zhao

PhD, Co-founder and Chief Executive Officer, Hangzhou JUST Biotherapeutics, China

Zhou Mingdong

CEO and Chief Scientist, Zensun, China

Zhengyu Yuan

President & Chief Executive Officer, MicuRx Pharmaceuticals Inc., China

George Hutchinson

Head of Global Distribution, Solentim, UK

Thomas Kelly

Scientist, Cell & Developability Sciences, Pharmaceutical Development & Manufacturing Sciences (PDMS), Janssen R&D, U.S.

Brian Hosung Min

Senior Vice President, Samsung Bioepis, South Korea

Jianwei Zhu

Chair Professor and Dean of School of Pharmacy, Shanghai Jiao Tong University (SJTU); Director of MOE Engineering Research Center of Cell Engineering and Antibody; President and Chief Executive Officer, Jecho Biopharmaceuticals, China

Steve Oh

Institute Professor and Scientist at the Bioprocessing Technology Institute, A-STAR, Singapore

Senior Representative, Prozyme

Xiaoming (Jerry) Yang

Senior Vice President, Process & Product Development, Just Biotherapeutics, China

Qinghai Zhao

Vice President, Technical Development & Manufacturing, Forty Seven, Inc., U.S.

Cuiyun Xu

Director, Upstream Process Development, Shanghai Henlius Biotech, Inc., China

Eric Chang

Head of Cell Line Development, JHL Biotech, Taiwan

Audrey Jia

Former FDA CMC Biologic Reviewer, U.S.

Minmin Qin

Senior Vice President and Head, CMC, Harbour BioMed, China

Weon-Kyoo You

Vice President and Head, R&D, ABL Bio, Inc., South Korea

James (Jianguo) Yang

Chief Executive Officer, Tayu Huaxia Biotech Medical Group, China

Doug Chen

Vice President, CMC, I-Mab Biopharma, China

Dong-Yup Lee

Associate Professor, College of Engineering, Sung Kyun Kwan University (SKKU), South Korea

Dr. Senyon Choe (Teddy)

Professor Biology, University of California San Diego (UCSD), USA, President/Director of joint Center for Biosciences, Korea

Dr. John E. Gil IV

Director, Head of Cell Line Generation, Shire HGT, U.S

Dr. Alvin Luk

Senior Vice President and Chief Medical Officer, Shanghai Henlius Biotech, Inc., China

Chen-Yuan Lin

Ward Director and Attending Physician at the Division of Hematology and Oncology, China Medical University Hospital, Taiwan

Dr Lin Shiwen

Vice President of Downstream Process Development, WuXi Biologics, China

Jerry Yang

SVP, Process & Product Development, Hangzhou JUST Biotherapeutics Co., Ltd., China

when & where

14 - 16 May 2019

Shanghai Marriott Hotel Parkview
333 Guang Zhong Road West, Jing’an District
Shanghai, 200072 China
Phone:+86 21 3669 8888
Fax:+86 21 3669 8668

Cartrina Wang 王洁琼 | Senior Sales Manager-EBC
mhrs.shamp.catering.asstmgr1@marriott.com
T: 86 21 3669 8666 | M:13585605981

https://www.marriott.com/hotels/travel/shamp-shanghai-marriott-hotel-parkview/

contact

Still have a question?

Speaking Opportunities
Genevieve Lim
+65-6508 2472
 
Genevieve.Lim@ibcasia.com.sg

Sponsorship Opportunities
Yvonne Leong
+65 6508 2489

Yvonne.Leong@ibcasia.com.sg

Media & Association Partnership Opportunities
Cloud He
+65 6508 2423
cloud.he@ibcasia.com.sg

sponsors

STAY UPDATED ON OUR NEWS & EVENTS

IBC Asia is Singapore's leading event organiser. We conceive, develop and promote our own B2B industry conferences and corporate training courses, and offer tailored managed event solutions.

Find out more